CES1 and head and neck squamous cell carcinoma: Our findings suggest that CES1 may reduce the sensitivity of HNSCC to cisplatin by disrupting lipid metabolic pathways, providing initial evidence of CES1’s impact on the treatment outcome of HNSCC.